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Abstract
Background: Sulfur mustard (SM) is a potent chemical vesicant warfare agent that remains a significant
military and civilian threat. Inhalation of SM gas causes airway inflammation and injury. In recent years,
there has been increasing evidence of the effectiveness of macrolide antibiotics in treating chronic airway
inflammatory diseases. In this study, the anti-cytotoxic and anti-inflammatory effects of a representative
macrolide antibiotic, roxithromycin, were tested in vitro using SM-exposed normal human small airway
epithelial (SAE) cells and bronchial/tracheal epithelial (BTE) cells. Cell viability, expression of
proinflammatory cytokines including interleukin (IL)-1β, IL-6, IL-8 and tumor necrosis factor (TNF), and
expression of inducible nitric oxide synthase (iNOS) were examined, since these proinflammatory
cytokines/mediators are import indicators of tissue inflammatory responses. We suggest that the influence
of roxithromycin on SM-induced inflammatory reaction could play an important therapeutic role in the
cytotoxicity exerted by this toxicant.
Results: MTS assay and Calcein AM/ethidium homodimer (EthD-1) fluorescence staining showed that
roxithromycin decreased SM cytotoxicity in both SAE and BTE cells. Also, roxithromycin inhibited the SM-
stimulated overproduction of the proinflammatory cytokines IL-1β, IL-6, IL-8 and TNF at both the protein
level and the mRNA level, as measured by either enzyme-linked immunosorbent assay (ELISA) or real-time
RT-PCR. In addition, roxithromycin inhibited the SM-induced overexpression of iNOS, as revealed by
immunocytochemical analysis using quantum dots as the fluorophore.
Conclusion:  The present study demonstrates that roxithromycin has inhibitory effects on the
cytotoxicity and inflammation provoked by SM in human respiratory epithelial cells. The decreased
cytotoxicity in roxithromycin-treated cells likely depends on the ability of the macrolide to down-regulate
the production of proinflammatory cytokines and/or mediators. The results obtained in this study suggest
that macrolide antibiotics may serve as potential vesicant respiratory therapeutics through mechanisms
independent of their antibacterial activity.
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Background
2,2'-Dichlorodiethyl sulfide (sulfur mustard, SM) is a vesi-
cant agent that was used as a chemical weapon during
World War I and more recently during the Iran-Iraq con-
flict; therefore, it remains a significant military and civil-
ian threat [1]. Damage due to SM inhalation has been
found to be dose-dependent [2,3]. At low to moderate
doses, the upper respiratory tract is mostly affected,
whereas at higher doses, damage is seen in the lower lung,
including the alveoli. SM-induced epithelial cell injury
and cell death in the tracheobronchial tree leads to
inflammation and sloughing of the mucosa during acute
stages. The clinical signs of SM inhalation include asthma,
chronic bronchitis, bronchiectasis, and pulmonary fibro-
sis [4]. Pulmonary damage and associated secondary
infections have been responsible for most fatalities [3]. At
present, there is no effective therapy for the victims due to
lack of understanding of the pathophysiological processes
of SM inhalation injury.
SM acts as an electrophile that alkylates cellular and extra-
cellular components of living tissue. As a result, complex
cellular events develop, including cell cycle arrest, the syn-
thesis and release of inflammatory mediators, and cyto-
toxicity. Following these cellular effects are tissue
responses such as inflammation and tissue damage [5].
The cause of the acute injury appears to be the premature,
sudden and massive release of destructive enzymes and
mediators of inflammation such as proinflammatory
cytokines, including interleukin (IL)-1β, IL-6, IL-8 and
tumor necrosis factor (TNF), and inducible nitric oxide
synthase (iNOS).
Proinflammatory cytokines are essential mediators of cell-
to-cell signals in physiological and pathological immune
responses and in the inflammatory response. Under nor-
mal conditions, these cytokines act as crucial signals in the
development of appropriate defenses. However, exagger-
ated or prolonged release can lead to pathological condi-
tions [6].
iNOS is the inducible isoform of nitric oxide synthase, the
enzyme that catalyzes the synthesis of nitric oxide (NO),
a short-lived free radical gas and a pleiotropic mediator
involved in the regulation of vascular smooth muscle tone
and proliferation, cell-mediated immunity, and inflam-
mation [7,8]. NO also plays a vital beneficial role in
wound healing through its functional influences on ang-
iogenesis, inflammation, cell proliferation, matrix deposi-
tion, and remodeling (for review see [9]). However, NO
can exert deleterious effects when it is inappropriately
generated or overproduced, and excessive amounts of NO
and its metabolites, such as peroxynitrite, may contribute
to the pathophysiology of inflammation and the resultant
tissue damage [10-12]. Production of NO is upregulated
in a variety of inflammatory diseases in which iNOS may
be involved [13,14].
Macrolides are a group of antibiotics that were initially
discovered because of their antibacterial properties. The
name "macrolide" is derived from their structure, which is
characterized by a macrocyclic lactone ring with various
amino sugars attached [15]. Roxithromycin is one of the
commonly used macrolides approved by the U.S. Food
and Drug Administration (FDA) [16]. In recent years,
there has been increasing evidence of the effectiveness of
macrolide antibiotics in treating chronic airway inflam-
matory diseases through mechanisms distinct from their
antibacterial activity (for review see [17]). Although the
mechanisms underlying this effect are still unclear, mac-
rolides have been shown to affect several pathways of the
inflammatory process, including the migration of neu-
trophils, the oxidative burst in phagocytes, and the pro-
duction of proinflammatory cytokines [18]. In this study,
the anti-cytotoxic and anti-inflammatory effects of roxi-
thromycin were tested using normal human small airway
epithelial (SAE) cells and bronchial/tracheal epithelial
(BTE) cells exposed to SM as in vitro models. Cell viability
and expression of proinflammatory cytokines and iNOS
were examined.
Results
Cytotoxicity
The MTS assay showed that SM exerted cytotoxicity in a
concentration-dependent manner in SAE and BTE cells. At
10  µM, no significant decrease in cell viability was
observed. At 100 µM, however, SM caused severe toxicity:
the viability of both cell types decreased to ~20% com-
pared with untreated cells 24 h after exposure (Fig. 1). In
Cytotoxicity of SM on SAE and BTE cells Figure 1
Cytotoxicity of SM on SAE and BTE cells. Cells were 
exposed to various concentrations of SM. Cell viability was 
measured using the MTS assay 24 h after exposure, and is 
expressed as a percentage of the control (unexposed cells, 
"C"). ***P < 0.001 versus control.BMC Cell Biology 2007, 8:17 http://www.biomedcentral.com/1471-2121/8/17
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contrast, roxithromycin reduced SM cytotoxicity in SAE
and BTE cells; incubation with 100 µM roxithromycin
increased the cell viability from ~20% to ~50% and
~60%for SAE and BTE cells, respectively, 24 h after expo-
sure to 100 µM SM (Fig. 2). No significant protective
effects of roxithromycin were observed at concentrations
lower than 10 µM. Roxithromycin alone had no effects on
cell viability of SAE and BTE cells at the concentration
range tested (0.1 µM – 100 µM, data not shown).
Calcein AM/EthD-1 staining showed a similar protective
effect of roxithromycin on SM-exposed SAE and BTE cells
(Fig. 3). Live cells are distinguished by the presence of
ubiquitous intracellular esterase activity, which converts
the virtually nonfluorescent cell-permeant calcein AM to
the intensely fluorescent calcein, producing an intense
uniform green fluorescence in live cells. Dead cells usually
are characterized by damaged membranes. EthD-1 enters
dead cells and undergoes a 40-fold enhancement of fluo-
rescence upon binding to nucleic acids, thereby producing
a bright red fluorescence in dead cells. EthD-1 is excluded
by the intact plasma membrane of live cells [19]. It is
apparent that exposure to 100 µM SM caused significant
cell death compared to control (unexposed) cells, whereas
the number of live cells increased substantially when 100
µM roxithromycin was included. Roxithromycin (100
µM) alone had no effect on cell viability. It was noted that
a significant number of cells died shortly after SM expo-
sure and thus detached from the slide, therefore the
observed cell density in samples treated with SM was sig-
nificantly lower than that of untreated samples. Also, a
large number of BTE cells enlarged after treatment with
SM and roxithromycin (Fig. 3). The reason for this mor-
phological change was unknown. Similar morphology
change was not observed in SAE cells.
Previous studies have implied that inflammatory
cytokines or mediators are involved in SM-induced inju-
ries and cell death. For example, suppressed expression of
the proinflammatory cytokines IL-8 and IL-6 in human
epidermal keratinocytes led to increased viability of SM-
treated cells [20]. In order to understand the mechanism
of the protective effect of roxithromycin and verify if the
decreased cytotoxicity is due, at least in part, to a reduced
inflammation, we further evaluated the effect of roxithro-
mycin on the expression of some inflammatory media-
tors, including proinflammatory cytokines and iNOS, at
the mRNA and/or protein level.
Cytokine protein expression
SM stimulated release of proinflammatory cytokines (IL-
1β, IL-6, IL-8 and TNF) from SAE and BTE cells into the
culture medium, albeit the extent of stimulation varied
among different cytokines. A time-course study of
cytokine release from cells exposed to ≤ 100 µM SM indi-
cated that, for both cell types, accumulation of all the
cytokines reached maximum levels 24 h after exposure
and remained stable for at least 48 h (data not shown).
Therefore, in the following experiments all the cytokines
were measured 24 h post-exposure. In general, it was
found that SM exposure induced proinflammatory
cytokine release in a concentration-dependent manner,
and roxithromycin inhibited the cytokine release, also in
a concentration-dependent manner. We noticed that the
Anti-cytotoxicity effect of roxithromycin on SM-treated SAE  and BTE cells Figure 3
Anti-cytotoxicity effect of roxithromycin on SM-
treated SAE and BTE cells. Cell viability was examined by 
Calcein AM/EthD-1 fluorescence staining 24 h after expo-
sure. The images for SAE cells (A) were captured by fluores-
cence microscopy whereas those for BTE cells (B) by 
confocal fluorescence microscopy. a) control (unexposed), b) 
100 µM roxithromycin, c) 100 µM SM, and d) 100 µM SM + 
100 µM roxithromycin. Cells stained green were alive and 
those stained red dead.
Effect of roxithromycin on SM cytotoxicity in SAE and BTE  cells Figure 2
Effect of roxithromycin on SM cytotoxicity in SAE 
and BTE cells. Various concentrations of roxithromycin 
were added to cells exposed to 100 µM SM. Cell viability was 
measured using the MTS assay 24 h after exposure, and is 
expressed as a percentage of the value obtained from cells 
unexposed to SM ("U"). ***P < 0.001 versus control (cells 
exposed to SM without roxithromycin, "C").BMC Cell Biology 2007, 8:17 http://www.biomedcentral.com/1471-2121/8/17
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absolute concentrations of cytokines measured in the cul-
ture supernatant were not consistent among replicated
experiments, probably due to differences in cell number,
confluence, age and other unknown factors. However,
when the concentration values were normalized relative
to control (unexposed) cells, the data became fairly con-
sistent. For this reason, the results are presented as per-
centages of the control in each experiment.
IL-8
Culture medium harvested from control SAE cell cultures
showed a gradual accumulation of this cytokine over time
that reached a plateau by 24 h. Upon treatment with <10
µM SM, no significant difference compared to the control
situation was observed. When treated with 100 µM SM,
however, a significantly higher amount of IL-8 was
released from SAE cells after 5 h and the accumulation of
the cytokine persisted up to 24 h after exposure (data not
shown). The final concentration, in the range of 20 ng/ml
– 30 ng/ml among experiments, was about 12-fold higher
than control cells. When roxithromycin was added to the
SAE cell culture medium before SM exposure, concentra-
tion-dependent inhibition of the SM-induced cytokine
secretion was observed (Fig. 4). Inhibition was observed
at a concentration as low as 1 µM and reached 71% when
the concentration of roxithromycin was 100 µM. Very
similar results were observed for BTE cells, except that the
highest concentration of IL-8 released into the medium
was in the range of 12–18 ng/ml when cells were exposed
to 100 µM SM.
IL-6
Similar to IL-8, culture medium harvested from control
SAE cell cultures showed a gradual accumulation of IL-6
over time that reached a plateau by 24 h. Upon treatment
with <10 µM SM, no significant difference compared to
the control situation was observed. When treated with
100 µM SM, however, a significantly higher amount of IL-
6 was released from SAE cells after 3 h and accumulation
of the cytokine persisted up to 24 h after exposure (data
not shown). The final concentration, in the range of 3 ng/
ml – 5 ng/ml among experiments, was 8-fold as high as
the control cells. When roxithromycin was added to the
SAE cell culture medium before SM exposure, concentra-
tion-dependent inhibition of SM-induced cytokine secre-
tion was again observed (Fig. 4). The inhibition was
observed at a concentration as low as 1 µM and reached
70% when the concentration of roxithromycin was 100
µM. Very similar results were observed for BTE cells,
except that the range of the highest concentration of IL-6
released into the medium was 4 ng/ml – 6 ng/ml for cells
exposed to 100 µM SM.
IL-1β
Unlike IL-6 and IL-8, IL-1β concentration in the culture
medium of SAE cells remained low even when the cells
were treated with 100 µM SM (<100 pg/ml). Nevertheless,
statistically significant concentration-dependent stimula-
tion by SM and concentration-dependent inhibition by
roxithromycin were observed. IL-1β concentration in the
culture medium increased to 6-fold compared with con-
trol cells 24 h after exposure to 100 µM SM (Fig. 4). Inhi-
bition by 100 µM roxithromycin was 69%. Very similar
results were observed for BTE cells, except that the highest
concentration of IL-1β released into the medium was ~80
pg/ml upon 100 µM SM exposure.
TNF
Similar to IL-1β, the concentration of TNF in the culture
medium of SAE cells also remained low (<50 pg/ml) even
when treated with 100 µM SM. Nevertheless, concentra-
tion-dependent stimulation by SM and concentration-
dependent inhibition by roxithromycin were observed.
TNF concentration in the culture medium increased ~4-
fold compared with control cells 24 h after exposure to
100 µM SM and inhibition by 100 µM roxithromycin was
73% (Fig. 4). Very similar results were observed for BTE
cells.
Cytokine mRNA expression
The mRNA expression levels of the proinflammatory
cytokines in SAE cells were in good agreement with their
protein expression patterns obtained from the ELISA
experiments. At the mRNA level, SM exposure also
induced proinflammatory cytokine expression in a con-
centration-dependent manner (data not shown). Expo-
Inhibition by roxithromycin of cytokine release from SM- exposed SAE cells Figure 4
Inhibition by roxithromycin of cytokine release from 
SM-exposed SAE cells. Various concentrations of roxi-
thromycin were added to cells exposed to 100 µM SM. 
Cytokine release was measured by ELISA 24 h after expo-
sure. Cytokine concentration is expressed as a percentage of 
the control (unexposed) cells. RXM, roxithromycin. *P < 
0.05, **P < 0.01, ***P < 0.001 versus cells exposed to SM 
only.BMC Cell Biology 2007, 8:17 http://www.biomedcentral.com/1471-2121/8/17
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sure to 100 µM SM increased cytokine mRNA expression
substantially (Fig. 5); for IL-6, IL-8 and TNF, the fold
increase was even higher than that of the protein release
level measured by ELISA (18-, 12-, and 8-fold vs. 12-, 8-,
and 4-fold, respectively). For IL-1β, the increase in its
mRNA level was slightly lower than its increase in protein
secretion (4-fold vs. 6-fold). Treatment with roxithromy-
cin of the SM-exposed cells decreased the mRNA levels.
This inhibitory effect of roxithromycin on mRNA expres-
sion was also concentration dependent (Fig. 5). Roxithro-
mycin at 100 µM was effective in reducing the mRNA
expression close to normal levels. Similar results were
obtained for BTE cells.
iNOS expression
iNOS is difficult to detect in airway epithelial cells by
western blotting or conventional immunocytochemical
methods, primarily due to its very low basal level expres-
sion. Results from real-time RT-PCR experiments indi-
cated that the iNOS mRNA level was 103 – 105 times lower
than that of some of the proinflammatory cytokines (data
not shown). In this study, we used quantum dots, a new
nano-scale material, as the fluorophore in the immunocy-
tochemical detection of iNOS. Because of the high stabil-
ity, intensity, and signal-to-noise ratio of the fluorescence
signal of quantum dots, iNOS was easily detectable in
both control (unexposed) and SM-exposed SAE and BTE
cells.
Using this new immunocytochemical method we have
found that, in both SAE and BTE cells, SM caused overex-
pression of iNOS, and this effect was inhibited by roxi-
thromycin. Shown in Fig. 6 are immunofluorescence
staining images using streptavidin-conjugated quantum
dots as detectors. Results from the statistical analysis of
the fluorescence signals are shown in Fig. 7. Exposure to
100 µM SM dramatically increased iNOS expression in the
two cell types (>10-fold). However, when 100 µM roxi-
thromycin was added to the culture medium before SM
exposure, iNOS expression was reduced substantially, to a
level comparable to the basal level. Roxithromycin (100
µM) alone had no effect on the signal level detected (data
not shown).
Discussion
SM inhalation causes acute airway inflammation and tis-
sue injury, presumably due to the premature, sudden and
massive release of destructive enzymes and mediators of
inflammation [3]. Currently there are no effective anti-
dotes for SM-induced inflammation and injury. Mac-
rolide antibiotics have been reported to have
immunomodulatory effects and to be effective in treat-
ment of chronic airway inflammation through actions
other than their bactericidal activity [17]. In this study, we
evaluated the potential of macrolide antibiotics as anti-
dotes for SM-induced injury and inflammation using rox-
ithromycin as a representative macrolide antibiotic for the
tests.
Airway inflammation and injury by SM is a complex phe-
nomenon that involves airway epithelial cells, cilia cells,
goblet cells and smooth muscle cells interacting with one
another under the control of a network of cytokines and
other mediators. SAE and BTE cells are considered the first
line of defense against inhaled chemicals as they are in
direct contact with these chemicals and participate in the
pathogenesis of airway injury through the release of oxi-
Effect of roxithromycin on iNOS expression in SM-exposed  SAE (A) and BTE (B) cells Figure 6
Effect of roxithromycin on iNOS expression in SM-
exposed SAE (A) and BTE (B) cells. a) control; b) 100 
µM SM; c) 100 µM SM + 100 µM roxithromycin. Representa-
tive 2D images from each sample are shown. Red spots are 
signals produced from quantum dots-detected iNOS. The 
scale bar in each image represents 20 µm.
Inhibition by roxithromycin of cytokine mRNA expression in  SM-exposed SAE cells Figure 5
Inhibition by roxithromycin of cytokine mRNA 
expression in SM-exposed SAE cells. Various concentra-
tions of roxithromycin were added to cells exposed to 100 
µM SM. Total RNA was isolated from cells 24 h after expo-
sure. Cytokine mRNA was quantified using real-time RT-
PCR. Results are expressed as a percentage of the control 
(unexposed) cells. RXM, roxithromycin. *P < 0.05, **P < 
0.01, ***P < 0.001 versus cells exposed to SM only.BMC Cell Biology 2007, 8:17 http://www.biomedcentral.com/1471-2121/8/17
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dants and inflammatory cytokines. It is therefore impor-
tant to understand the interaction between these cells and
the chemical insult, as well as their response to an insult/
therapeutic treatment combination such as SM/roxithro-
mycin.
The effect of roxithromycin on SM-induced cell injury was
first tested by the MTS cell viability assay and the Calcein
AM/EthD-1 fluorescence staining viability assay. The MTS
assay showed a concentration-dependent cytotoxicity
induced by SM in SAE and BTE cells. For both cell types,
100 µM roxithromycin alleviated the SM cytotoxicity. Cal-
cein AM/EthD-1 fluorescence staining confirmed these
results. Together, these results demonstrated the protec-
tive effect of roxithromycin against SM-induced injury.
Proinflammatory cytokines play a major role in both
acute and chronic inflammatory processes, including
those produced by SM. However, these cytokines, particu-
larly when produced in excess, can be pathogenic. Previ-
ous studies demonstrated that in vivo damage to the skin
by SM results in an immunological response defined by
increased gene expression of the inflammatory cytokines
[6]. In this study we examined the expression of four
major inflammatory cytokines, IL-1β, IL-6, IL-8, and TNF.
The basal expression levels of the four cytokines were all
very low in normal SAE and BTE cells, although IL-6 and
IL-8 accumulated continuously in the culture medium
from unstimulated cells grown in cell culture. However,
exposure of SAE and BTE cells to SM in vitro resulted in a
rapid increase in the mRNA levels in the cell and the
release of the cytokine protein into culture supernatants
for all of the four cytokines. Both the mRNA expression
and protein release increased several fold in SM-exposed
cells relative to unexposed cells for IL-1β and TNF, and
increased 10- to 20-fold in the cases of IL-6 and IL-8.
Although the final supernatant concentrations for IL-1β
and TNF remained low (<100 pg/ml), the concentrations
of IL-6 and IL-8, on the other hand, reached very high lev-
els (10 ng/ml – 30 ng/ml). These results suggest that these
two inflammatory mediators may play a major role in the
mediation of the inflammatory and immune responses
initiated by SM inhalation.
In light of the potential role of IL-6 and IL-8 in inflamed
airway epithelium, an understanding of the regulation of
their production may provide valuable information for
treatment of SM exposure. A significant increase in IL-8
release was also reported in human epidermal keratinoc-
ytes following SM exposure and has been proposed as a
biomarker for SM-induced inflammation [21]. It is also
intriguing to note that IL-6 was reported as an anti-inflam-
matory cytokine in human plasma samples [22] and in
human monocytes [23]. Therefore, it is reasonable to
speculate that IL-6 is a pleiotropic cytokine whose anti- or
pro-inflammatory properties depend on the cell type from
which it is produced and to which it is targeted.
iNOS has been suggested to be an important biomarker of
inflammation, as its overexpression leads to excessive pro-
duction of NO, which contributes to the pathophysiology
of inflammation and the resultant tissue damage [10]. NO
is involved in several types of acute and chronic inflam-
mation [24]. Overproduction of NO by type II NOS or
iNOS is associated with the development of airway
inflammation [14]. However, the basal level expression of
iNOS was low in SAE and BTE cells and therefore was dif-
ficult to detect by immunocytochemistry using conven-
tional fluorophores (Texas Red, fluorescein, etc.). To
improve signal stability and quantitation, an optically sta-
ble, new class fluorophore for immunocytochemical
detection was employed in this study. Detection of iNOS
was based on fluorescence from streptavidin-linked inor-
ganic semiconductor nanocrystals of cadmium selenide
[(CdSe)ZnS]. As fluorescence of nanomaterialfluoro-
phores was significantly brighter and more photostable
than organic fluorophores such as Texas Red and fluores-
cein [25,26], we were able to detect iNOS in both unex-
posed and SM-exposed SAE and BTE cells.
The reduced overexpression of proinflammatory
cytokines and iNOS by roxithromycin in SM-exposed SAE
and BTE cells is in agreement with previous in vivo and in
vitro studies (for a complete review see [27]) and further
supports the contention that macrolides can inhibit the
production of proinflammatory mediators and cytokines.
Relative fluorescence intensity showing quantitatively the  effect of roxithromycin on iNOS expression in SM-exposed  SAE and BTE cells Figure 7
Relative fluorescence intensity showing quantita-
tively the effect of roxithromycin on iNOS expres-
sion in SM-exposed SAE and BTE cells. Average 
fluorescence intensities were computed from cells (n ≥ 10) in 
each sample and are expressed relative to the control (unex-
posed cells). RXM, roxithromycin. ***P < 0.001 versus cells 
exposed to SM only.BMC Cell Biology 2007, 8:17 http://www.biomedcentral.com/1471-2121/8/17
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This suppressive effect of roxithromycin may not be
accounted for by its antimicrobial properties but rather by
its anti-inflammatory actions, as evidenced by the fact that
other antibiotics, such as amoxicillin, cefaclor, penicillin,
and cephalosporin, had no such effects even at high con-
centration (data not shown). Thus the immunomodula-
tory effects of antibiotics appear to be specific to
macrolides. Similar findings were made by Kohri et al.
[28].
The protective effect of roxithromycin on SM cytotoxicity
could be explained, at least in part, by its ability to inhibit
the overexpression of pro-inflammatory cytokines and
mediators. As mentioned previously, Qabar et al. [20]
reported that suppressed expression of the proinflamma-
tory cytokines IL-8 and IL-6 in human epidermal keratino-
cytes, mediated by overexpressing the anti-inflammatory
cytokine IL-10, led to increased viability of SM-treated
cells. Also, 1-alpha, 25-dihydroxyvitamin D3 enhanced
cell proliferation in human skin cells stimulated with SM
by suppressing expression of the inflammatory mediators
IL-6 and IL-8 [29]. On the other hand, Stone et al. [30]
reported that inflammatory cytokines, such as TNF-α and
IL-1β enhanced SM toxicity on murine macrophages. The
protective effect of roxithromycin seen in this study, an
increase in cell viability by ~2.5 and ~3.0 times for SAE
and BTE cells respectively, is higher than that of 1-alpha,
25-dihydroxyvitamin D3 on HEK cells, an increase of ~1.5
times in cell proliferation [29]; although the results are
not directly comparable as the cells used in the two studies
are different.
The subcellular mechanism of the anti-inflammatory
effect of macrolides remains unknown. However, it is well
known that the expression of several genes involved in the
immune and inflammatory response (e.g., iNOS, TNF, IL-
1, IL-6, IL-8) are regulated at the transcriptional level by
nuclear factor-κB (NF-κB) (for a recent review, see [31]).
Thus, it is conceivable that macrolide antibiotics may act
as anti-inflammatory agents by preventing the activation
of NF-κB. Ichiyama et al. [32] demonstrated that clarithro-
mycin, another macrolide widely used clinically, inhibits
NF-κB-dependent reporter gene expression in transfected
pulmonary epithelial cells, providing direct evidence in
support of specific effects of macrolides on NF-κB activa-
tion. However, it is now held that the molecular mecha-
nism(s) by which macrolides inhibit pro-inflammatory
cytokine responses in the respiratory epithelium varies
depending upon the macrolide used, the activating stimu-
lus, and the cell type examined [27]. Thus, further studies
are required to determine whether NF-κB is the target
molecule for roxithromycin in the signal transduction
pathway in SM-exposed SAE and BTE cells.
Conclusion
Our results demonstrate that roxithromycin has anti-cyto-
toxic and anti-inflammatory activities in human airway
epithelial cells. These effects of roxithromycin likely
depend on its ability to prevent the overproduction of
proinflammatory cytokines and mediators. Thus, mac-
rolide antibiotics can exert therapeutic effects independ-
ent of their antibacterial activity. In view that there are
currently no effective antidotes for SM inhalation injuries,
the results of the present study suggest that macrolide
antibiotics may serve as potential vesicant respiratory
therapeutics.
Methods
Reagents
Sulfur mustard (2,2'-dichlorodiethyl sulfide; 4 mM) was
acquired from the US Army Edgewood Research, Develop-
ment and Engineering Center (Aberdeen Proving Ground,
MD). Roxithromycin was obtained from Sigma (St. Louis,
MO) and dissolved in ethanol at a concentration of 10
mM and then diluted to the desired concentrations using
culture medium.
Cell culture
Normal human SAE cells and normal human BTE cells
were obtained from Cambrex (Walkersville, MD). The
homogeneity of these cells was vigorously tested and
assured by the manufacturer. Cells were grown in the opti-
mized media as formulated by the manufacturer and cul-
tured at 37°C under humidified 5% CO2. Experiments
were performed on cells of the fourth passage. For all
experiments, cells were grown to ~90% confluence except
for the immunofluorescence staining experiment, where
cell density was 30 – 40% confluence.
Sulfur mustard exposure
Cells were seeded in 6-, 12-, 24- or 96-well plates and
allowed to grow for 5 to 6 days to near confluence. The
medium was replaced with fresh medium before expo-
sure. SM was then added to the final concentrations indi-
cated. The culture plates were maintained at room
temperature in a chemical fume hood for 1 h then trans-
ferred to an incubator of 37°C with 5% CO2.
Cytotoxicity assay
Cytotoxicity was measured by either the MTS assay [33] or
Calcein AM/ethidium homodimer-1 (EthD-1) staining
[19]. The CellTiter 96 Aqueous One Solution Cell Prolif-
eration Assay kit from Promega (Madison, WI) was used
for the MTS assay and instructions from the manufacturer
were followed. Briefly, cells were seeded in a 96-well plate
at 1 × 104 cells/well and allowed to adhere overnight at
37°C with 5% CO2, then cells were exposed to SM with or
without roxithromycin and incubated for another 24 h.
After adding 20 µl of assay reagent to each well that con-BMC Cell Biology 2007, 8:17 http://www.biomedcentral.com/1471-2121/8/17
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tained 100 µl medium, cells were further cultured for 3 h
and the resultant absorbance was recorded at 490 nm
using a 96-well plate reader. Each experiment was per-
formed with eight independent replicates and repeated
three times. For the Calcein AM/EthD-1 staining method,
the LIVE/DEAD Viability/Cytotoxicity Kit from Molecular
Probes (Eugene, OR) was used and protocols provided by
the manufacturer were adopted.
Enzyme-Linked Immunosorbent Assay (ELISA)
ELISA kits from BD Biosciences (San Diego, CA) were
used for the quantification of IL-1β, IL-6, IL-8, and TNF in
the culture medium following the manufacturer's instruc-
tions. The results are expressed as a percentage of the con-
trol (cells unexposed to SM) and represent the mean ± SE
of three experiments performed in triplicate.
Real-Time RT-PCR
Total RNA was isolated from ~1 × 107 cells of each sample,
using the RNAqueous-4PCR kit from Ambion (Austin,
TX) following the manufacturer's instructions and with
the optional DNase I treatment step to avoid contamina-
tion with genomic DNA. Reverse transcription of mRNA
was carried out using the High-Capacity cDNA Archive Kit
from Applied Biosystems (Foster City, CA), using 1 µg of
total RNA in an 100 µl final volume. Real-time PCR was
carried out on the 7500 Fast Real-Time PCR system of
Applied Biosystems using TaqMan Gene Expression
Assays primer/probe sets and the standard thermal-
cycling conditions for relative quantification designed by
the manufacturer. Results were analyzed with the SDS
software v1.3.0 on the system using the   method.
β-actin was used as an endogenous control to correct for
variations in input RNA amount and cDNA amplification
of different samples.
Immunofluorescence staining
Cells were grown on slide to 30% – 40% confluence and
exposed to SM with or without roxithromycin. After 24 h,
cells were rinsed with 10 mM Tris, 150 mM NaCl, pH 7.4
(TBS) and fixed in 10% zinc formalin solution. The slides
were then processed robotically on the BenchMark XT
IHC/ISH workstation of Ventana (Tucson, AZ) to react
with the primary and secondary antibodies. The primary
antibody used was mouse anti-iNOS MAb from BD Bio-
sciences, and was diluted 1:1000 in TBS + 0.5% (w/v) Tri-
ton X-100 (TBST). The secondary antibody was pre-
diluted biotinylated rabbit anti-mouse IgG from Ventana.
iNOS signals were detected by quantum dot-streptavidin
conjugates (streptavidin-Qdot655), which was diluted
1:200 with the Qdots incubation buffer from Invitrogen
(Carlsbad, CA). The fluorescence signals were visualized,
captured and processed as reported previously [25,26].
Data analysis
For comparative studies, Student's t-test (unpaired) or
one-way ANOVA tests (with Bonferroni post test if P <
0.05) were used for statistical analysis. Differences were
considered statistically significant if a P value of < 0.05
was achieved.
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